The Future of Disease Management: A New Landscape for Integrated Care

The Disease Management Colloquium

Jefferson Medical College

Thomas Jefferson University

June 24, 2005

Sam Nussbaum, M.D.

Executive Vice President and Chief Medical Officer

WellPoint, Inc.



Agenda

- Chronic Illness: Complex and Costly
- Drivers of Health Care Costs
- Vision of the Future of Health Care
- Strategies for Health Improvement
- Transition to Progressive Care Management
- New Landscapes for Disease Management
 - Breakthrough Technology
 - Specialty Pharmacy
 - Pay for Performance
 - Consumer Engagement




Who Is WellPoint?

- Largest health benefits company in the nation
- More than 28.5 million medical members
 - Blue plans in 13 states
 - UniCare across the country
 - HealthLink in 7 states
- Major specialty businesses: pharmacy, dental, vision, life/disability, behavioral health, EAP, workers' compensation, Medicaid
- Nation's 2nd largest Medicare contractor
- More than 38,000 associates




U.S. Health Status Continues to Deteriorate

Lifestyle choices biggest contributor to Americans' health status



Prevalence of Chronic Illnesses


More than 130 million Americans suffer from chronic conditions and could benefit from disease management programs



Costs of Chronic Conditions

Chronic Condition	Prevalence	Annual Cost
Diabetes	16 million Americans	\$105 billion in health expenses11 million lost work days
Heart Disease	60 million Americans	\$300 billion in health expenses1 million deaths
Asthma	14 to 15 million Americans	 \$5.1 billion in medical expenses 2.1 million missed work days
Depression	17 million Americans	• \$43 billion

Health Care Spending as Percent of GDP



Drivers of Health Care Costs

- Population dynamics: aging population with chronic diseases
- Medical technology and treatment advances
- Medical errors; poor quality care
- Health professional shortages; medical malpractice litigation
- Consumer education, information, navigating the complex system
- Unnecessary care; duplication of medical services
- Administrative costs: hospitals, insurers, medical practices
- Physician and hospital compensation incentives



The Quest for Affordable, High-Quality Health Care



- HMOs
- Contracting in setting of excess capacity
- Aggressive medical management



- Capitation
- Physician management companies
- Vertically integrated delivery (and financing) systems



- "Boutique" delivery models
- Consumer-directed health care and HSAs
- High performance networks
- Rewarding quality performance
- Disease and care management



Vision of the Future of Health Care

Managing Components

Current

Episode of Care

Hospital center of delivery system

Focus on quality of service

Access, amount of care gold standard

Managing Overall Health

Evolving

Population health, disease prevention, integrated care

Proactive primary care integrated with specialty services

Focus on quality of care: improved outcomes

Consumer engagement and decision-making




Strategies for Health Improvement

% of WellPoint Members

50%	20%	25%	4%	1%
Well Members	Low Risk Members	Moderate Risk Members	High Risk, Single or Multiple Diseases	Complexly III
10%	10%	25%	30%	25%

% of Health Care Costs





Transition to a Progressive Care Management Model

Innovative medical management strategies support members as they navigate complex health care system

Traditional



- **Benefit-centered**
- Reactive
- **Cost-containment**
- Acute episodes of care
- **Diagnosis-driven**
- Minimal member and physician contact
- Arranging, authorizing, approving

Progressive

- Member-centered
- Proactive and anticipatory
- Quality outcomes
- Long-term management
- Interplay of illness and environment
- Direct member contact, physician collaboration
- Assessing, planning, coordinating, monitoring, evaluating

WELLPOINT


Integrating Breakthrough Technology with DM

What Does Innovation in Health Care Do?

Innovation	Benefit
Hip, Knee Replacement	Improves Quality of Life
Cardiac Procedures, Implanted Defibrillators	Increases Length of Life
Advanced Diagnostic Studies, Medical Informatics, Computerized Medical Records	Improves Quality of Care
Minimally Invasive Surgery, Estrogen Receptor Therapy	Lowers Total Health Care Costs

Introduction of New Medical Technologies and Therapies

- If effective, promote as consistent best practice
- If ineffective, don't do it
- If insufficient evidence, assess in clinical trial
- Pharmaceutical companies, NIH, device manufacturers, CMS, health plans should support clinical trials and registries





Case Study: Colorectal Cancer

Colorectal cancer illustrates the complexities of advancing science and accelerating health care costs.

- Third most common cancer (150,000 new cases / year) and second most common cause of death (57,000 deaths / year).
- Over 90% of colon cancer deaths are preventable, yet fewer than 50% of people over 50 undergo screening.
- Specific molecular events of carcinogenesis provide window of opportunity of 8 to 10 years for diagnosis.
- Specific DNA alterations occur as discrete steps in cascade and can be measured by new molecular tests.
- New screening techniques (i.e., CT colonography) increasingly find small tumors. This technology may supplant more invasive, expensive colonoscopy.
- Avastin, an FDA-approved drug for metastatic colon cancer, costs \$50,000 a year and prolongs life 8 to 10 months.



A Look to the Future for Technology Introduction

- More rapid introduction of novel technologies and therapies
- Greater emphasis on health services research and clinical trials (cooperative trials, FDA, AHRQ)
- New generation of physicians who recognize life-long learning and rapidly adopt new technologies
- Patients are informed health care consumers
- Technology integrated with care management models
- Health plans and Medicare support clinical trials and registries to arrive at evidence-based decision-making



Integrating Specialty Pharmacy with DM

Specialty Pharmacy: A Definition

- Chronic, expensive, uncommon diseases
- Expanding clinical indications such as anemia in cancer and treatment of certain types of arthritis
 - Annual cost per patient range: \$8,000 to \$150,000 or more
- Usually delivered non-orally (e.g., injection, infusion)
- Special handling (temperature controlled, overnight)
- High-touch patient interface (compliance, monitoring, education linked to care management programs)
- Complex reimbursement



Specialty Pharmacy

Market expansion and cost of specialty, biotech drugs will accelerate.

- 1. Oncology
- 2. HIV / AIDS
- 3. Multiple Sclerosis
- 4. Rheumatoid Arthritis
- 5. Hemophilia
- 6. Hepatitis C
- 7. Resp Syncytial Virus
- 8. Infertility
- 9. Gaucher Disease
- 10. Crohn's Disease
- 11. Immune Disorders
- 12. Growth Hormone Def.
- 13. Pulmonary Hypertension

- 200 on market by end of 2005; product revenue of \$50 billion; 600 drugs in development.
- Average monthly cost of drug > \$1,000, compared to \$45 for traditional drug;
 Cerezyme costs \$250,000 yearly.
- Increases of 25-50% in cost trends
- Currently:
 - 156 clinical indicators
 - 36 disease categories
 - 22 physician specialties



Specialty Pharmacy: Current Environment

- \$35 billion in 2004, growing 20% to 35% annually
- Associated with biotech (the fastest-growing area of the pharmaceutical industry)
- Expected to climb to > 25% of employers' total drug costs over next few years
- Distribution channel in transition
 - Traditional: retail drugstores, hospitals, physicians, home health
 - Emerging: specialty pharmacies, infusion centers




Specialty Rx: Current Environment

Rapid Growth

2004 Outpatient Pharmacy Spend \$190 Billion

Data on file: CuraScript



600 600 r 500 **Jumber of Drugs** 400 369 Biotech Drugs in Development 300 240 Biotech Drugs on the Market 197 200 100 92 100 29 PhRMA, International Federation of Pharmaceutical Wholesalers & Biotech 1990 1995 2000 2005 **Industry Organization**

Estimated



Current Environment: Therapy Examples

Chronic Condition	Medications	Avg. Annual Cost (AWP)
Growth Hormone Deficiency	Nutropin, Humatrope, Genotropin, Norditropin	\$18,000 - \$20,000
Hepatitis C	Rebetron, Pegasys, Peg-Intron, Infergen	\$24,000 - \$30,000
Infertility	Fertinex, Lupron, Gonal F, Follistim	\$10,000 - \$20,000
Multiple Sclerosis	Betaseron, Avonex, Rebif, Copaxone	\$12,000 - \$15,000
Oncology, BMT, HIV/AIDS	Neupogen, Procrit, Neulasta, Epogen, Aranesp, Gleevec, Iressa, Fuzeon	\$5,000 - \$20,000
Hemophilia	Recombinant Blood Factor Products	\$150,000 +
Rheumatoid/Psoriatic Arthritis	Enbrel, Remicade, Humira, Kineret	\$15,000 - \$20,000
Gaucher Disease	Cerezyme, Zavesca	\$150,000 - \$225,000
Pulmonary Hypertension	Flolan, Tracleer, Remodulin	\$30,000 - \$100,000
Lysosomal Storage Disorders	Fabrazyme, Aldurazyme	\$175,000 - \$200,000
Psoriasis	Amevive, Enbrel, Raptiva	\$12,000 - \$20,000
Allergic Asthma	Xolair	\$10,000 - \$15,000

Specialty Pharmacy: Care Coordination


- Clinical care coordination ensures the appropriate use of specialty drugs
- Inappropriate utilization is eliminated
- Persistency and completion of therapeutic treatment plans are improved
- Regular interactions with patient improves clinical awareness and outcomes, engaging the patient in care
- Comprehensive support system for the patient




Health Care Quality: Institute of Medicine Reports

"To Err is Human" and "Crossing the Quality Chasm"

- Medical errors account for 50,000 to 100,000 deaths each year in hospitals (more than breast cancer, AIDS or motor vehicle accidents)
- U.S. health care system does not apply evidenced-based medical knowledge; no system of care for chronic illness








Integrating Financial Incentives with DM

- Dominant methods don't achieve goal of clinical quality in health care
 - Fee-for-service payments encourage overuse
 - Capitated payments encourage underuse
 - Neither systematically rewards excellence in quality
- Strategy undercut by difficulties in measuring quality and adjusting for risk in way that is meaningful to consumers
- Some early experiments in rewarding quality with more favorable payments, but limited



P4P Programs at WellPoint: Quality Vision



Quality broadens the dialogue beyond fees to building a foundation of trust



P4P Programs at WellPoint

Partnerships with physicians and hospitals on quality incentives

PCP Programs

Focused on primary care physicians. Typical major components:

- ✓ Clinical outcomes
- ✓ Evidence-based medical procedures
- ✓ Generic prescribing rates
- ✓ Technology & streamlined administrative processes
- √ Patient satisfaction

Specialist Programs

Focused on specialty care physicians. Early initiatives in: Ob/Gyn, Cardiology, Orthopedics. Measures similar to PCP programs:

- ✓ Clinical outcomes
- ✓ Evidence-based medical procedures
- ✓ Generic prescribing rates
- ✓ Technology & streamlined administrative processes
- ✓ Patient satisfaction

Hospital Programs

Focused on acute care hospital, typically full service facilities. Hospital programs typically have the following components:

- ✓ Patient safety
- ✓ Clinical outcomes
- √ Patient satisfaction



WellPoint Coronary Services: Extensive Quality Outcomes Metrics

Coronary Artery Bypass Grafts (CABG)

- number of procedures
- mortality
- return to OR
- saphenous vein use
- infections

Percutaneous Transluminal Coronary Arteriography (PTCA)

- number of procedures
- repeat PTCA
- failed PTCAs which go onto CABG within 24 hours
- primary PTCA for acute myocardial infarction

Myocardial Infarction (MI)


- number of patients with MI
- time to PTCA
- time to thrombolytic therapy from ER (door to drug)
- aspirin use in 24 hours
- mortality
- ß-blocker use
- critical pathway use
- number with LVEF < 40%
 prescribed ACE inhibitors



Hospital Quality Programs


Rewarding high scores creates tangible incentive for quality improvement

Reimbursement Increase Schedule



California Scorecard Overview

Measurement I	Period	Specialty Care	<u>Care</u> Management	Generic Prescribing	Administrative*
	Score				
07/15/2003	Your Rate	93%	73%	45%	Meets All Standards
	Peer Mean	72%	65%	37%	N/A



Clinical Indicator	Observed Care	Eligible Cases	(Confidence Interval)	Peer Mean
Breast Cancer Screening	49	58	84%	82%
Cervical Cancer Screening	68	84	81%	78%
Colorectal Cancer Screening	26	45	58%	59%
Compliance with Lipid Lowering Drugs	11	22	50%	43%
Diabetes: Diabetic Retinal Exam	5	11	45%	32%
Diabetes: Glycosylated Hemoglobin for Diabetics	10	11	91%	71%
Composite Total (Confidence Interval)	169	231	73% (67% - 79%)	65%

Composite Ratings	Associated Fee Schedule Adjustment	Maximum Possible Fee Schedule Adjustment
Clinical Composites "Above Peer Mean" in each composite scored ⁵	8%	
One "Above Peer Mean" and One "At Peer Mean"Clinical Composite	6%	8%
"At Peer Mean" in each composite scored	4%	
Generic Prescribing Composite "Above Peer Mean"	2%	2%
Administrative Composite "All Standards Met"	2%	2%
TOTAL PQIP INCENTIVE POSSIBLE P	rudent Buyer +	12%

Administrative Composite	Meets All Standards			
	Administrative Indicators			
Tax ID Number (TIN)	Submit Claims Electronically			
77-0139017	78%	198	Yes	
77-0324855	94%	13		
Indicator Standard	> 85% in any TIN	> 0 hits in any TIN	Yes	
Your Performance	Standard Met	Standard	Above Peer Mear	


Regional Benchmarks National Benchmarks Percentiles: 10 - 25th 25 - 75th 75 - 90th BCC Physician Specialty: FAMLY PRACTICE County: ALL COUNTIES Primary/ Secondary Average Rate How You Compare 100% ACE Inhibitor use in CHF Primary 100% Cervical cancer screening Primary 82% 78% At Peer Mean **Below Peer Mean** WELLPOINT.

Rewarding Clinical Performance: Timing Is Right


- Increasing purchaser interest in quality as a factor in buying decisions
- IOM reports and Medicare reform boost quality measurement; Medicare launched new P4P physician program in April
- President's EMR goal to improve quality
- AMA, JCAHO and MedPAC focusing their constituencies on P4P
- Regional coalitions forming to improve market adoption of P4P (Leapfrog, IHA, Bridges to Excellence)



Consumer Directed Health Care



CDH: Members engaged in their own care



CDH: Giving consumers control of health care decisions and dollars




- Helping consumers take an active role in their health and health care
- Giving consumers control of routine health decisions and dollars
- Internet-based tools help individuals better manage their care and medical expenses through informed decision-making



The Healthcare Advisor: Easy-to-Use Decision-Making

- User-friendly with context-consistent data and information
- Research more than 150 different medical conditions and procedures
- Compare hospital quality





The Healthcare Advisor: Side-by-Side Comparison

- Clinical outcomes
- Patient safety
- Hospital reputation
- Market-specific studies
- Hospital comments

Hospital Clinical Experience and Outcomes for Selected Procedure Coronary Artery Bypass Graft Surgery (Heart Bypass): Inpatient					
	UCLA MEDICAL CENTER	CEDARS-SINAI MEDICAL CENTER	SANTA MONICA UCLA MEDICAL CENTER		
Patients Treated in One Year	160	428	56		
Severely Ill Patients Treated in One Year	129	352	42		
Complication Rate	#	As Expected	As Expected		
Post-Operative Infection Rate	As Expected ‡	Worse than Expected	As Expected		
Mortality Rate	As Expected #	As Expected	As Expected		
Patient Safety Standard for Procedure Experience	Good Early Stage Effort	Good Progress Toward Standard	Good Early Stage Effort		
California Bypass Surgery Reporting Program	As Expected	As Expected	As Expected		





CDH and **DM**: A New Landscape

- Allocating coverage dollars wisely
- Making rational treatment and provider decisions
- Using reliable and easily understood quality metrics
- Trading up to better treatments when value is demonstrated
- Complying with treatments
- Consumers satisfied with their care



Realizing the Future of Disease Management

"Discovery consists of seeing what everybody has seen and thinking what nobody has thought."

Albert Szent-Gyorgyi
1937 Nobel Laureate in Medicine

